Dragoljub Bankovic Thesis DexCom, Inc. (NASDAQ:DXCM), is a company focused on the development and commercialization of medical devices for continuous glucose measurement (CGM). Late last month, the company reported Q2 earnings, revealing a decline in new customers as well as a decline in U.S. revenue/customer, which triggered the company to decrease their 2024 revenue guidance from $4.2–4.35 billion (17 — 21% organic growth) to $4.0–4.5 billion (11 — 13% organic growth). To balance the guidance update, ...

It might be a great time to buy low.Earnings season can be a volatile time in the stock market. Some corporations produce financial results that are impressive enough to send their share prices soaring, while others move in the exact opposite direction. Medical device specialist DexCom (DXCM -7.88%) and social media platform Pinterest (PINS -0.21%) are in the latter group.Both failed to impress investors with their second-quarter results. DexCom's stock dropped by about 40% in one day, while Pinterest's dec ...

RADNOR, Pa., Aug. 7, 2024 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of DexCom, Inc. (NASDAQ: DXCM) ("DexCom").On July 25, 2024, after the market closed, DexCom announced disappointing earnings results for its second quarter of 2024 and slashed full year revenue guidance from $4.35 billion to $4 billion-$4.05 billion. In addressing the results, DexCom stated that the c ...

NEW YORK, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into DexCom, Inc. (NASDAQ: DXCM) for potential violations of the federal securities laws. If you invested in DexCom, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/dexcom-inc. Why Did DexCom’s Stock Drop? DexCom develops glucose monitoring systems for diabetes management. The company discussed how its recent sales force re ...

NEW YORK, Aug. 04, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into DexCom, Inc. (NASDAQ: DXCM) for potential violations of the federal securities laws. If you invested in DexCom, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/dexcom-inc. Why Did DexCom’s Stock Drop? DexCom develops glucose monitoring systems for diabetes management. The company discussed how its recent sales force re ...

Recently, weight loss and diabetes watch company DexCom Inc. NASDAQ: DXCM stock plummeted by over 44% on a surprisingly bad quarterly earnings report. Management guided lower – much lower – than analysts had expected to see revenue and earnings per share (EPS), and it all had to do with the decreasing demand for the company’s medical devices, which are being replaced more and more by effective medicine lately.Hims & Hers Health TodayHIMSHims & Hers Health$17.56 -0.95 (-5.13%) 52-Week Range$5.65▼$25.74Price ...

LOS ANGELES, Aug. 2, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of DexCom, Inc. ("DexCom" or "the Company") (NASDAQ: DXCM) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. DexCom announced its second quarter earnings on July 25, 2024, including revenue that f ...

RADNOR, Pa., July 31, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of DexCom, Inc. (NASDAQ: DXCM) (“DexCom”). On July 25, 2024, after the market closed, DexCom announced disappointing earnings results for its second quarter of 2024 and slashed full year revenue guidance from $4.35 billion to $4 billion-$4.05 billion. In addressing the results, DexCom stated that ...

RADNOR, Pa., July 31, 2024 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of DexCom, Inc. (NASDAQ: DXCM) ("DexCom").On July 25, 2024, after the market closed, DexCom announced disappointing earnings results for its second quarter of 2024 and slashed full year revenue guidance from $4.35 billion to $4 billion-$4.05 billion. In addressing the results, DexCom stated that the ...

Core Insights - DexCom, Inc. is under investigation for potential violations of federal securities laws following disappointing earnings results and a significant stock price drop [1][2]. Company Performance - DexCom reported second-quarter earnings for 2024 that fell short of expectations, leading to a reduction in full-year revenue guidance from $4.35 billion to a range of $4 billion to $4.05 billion [2]. - The company attributed its poor performance to challenges in restructuring its sales force, although some analysts suggested that the rising popularity of GLP-1 weight loss drugs may have also affected sales [2]. Stock Market Reaction - Following the earnings announcement, DexCom's stock price experienced a sharp decline, closing at $107.85 per share on July 25, 2024, and dropping to approximately $66.60 per share by the next trading day, marking a decrease of $41.25 per share or 38% [2]. Legal Context - Bleichmar Fonti & Auld LLP is investigating DexCom and encourages investors to seek additional information regarding potential legal options [1][3]. - The law firm operates on a contingency fee basis, meaning shareholders will not incur costs unless the case is successful [3]. Firm Background - Bleichmar Fonti & Auld LLP is recognized as a leading international law firm specializing in securities class actions and has achieved significant recoveries in past cases, including over $900 million from Tesla's Board of Directors [4].